Daily happenings?., page-464

Just had a watch of the Reach Markets interview. SYC being very cautious in my opinion. At current share price though there's huge upside. Thing of interest as an investor to me in the near term will be the framing of any announcements post the FDA meeting. Steven was very clear in pointing out the FDA won't give any definitive statement that the next trial will be registrational so leaves a degree of subjectivity around communications related to these conversations. May be some reading the tea leaves initially before it is known where the phase 2 trial could take things.